RxDoctor Payments Data

Vu Nguyen, MD

Physical Medicine & Rehabilitation · Birmingham, ALNPI 1952335234

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Merz Pharmaceuticals, LLC at 42.7% of the total. Reporting peaked in 2023 at $269 and has fallen 69.0% since, to $84 in 2025.

$944in general payments, 2019–2025

Across 15 payments — averaging $62.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz Pharmaceuticals, LLC$403
  • Merz North America, Inc.$262
  • Pacira Pharmaceuticals Incorporated$170
  • Ipsen Biopharmaceuticals, Inc$96
  • Conmed Corporation$13
$73,891in research payments, 2019–2025

Across 43 payments — averaging $1718.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merz Pharmaceuticals, LLC$52K
  • Sunovion Pharmaceuticals Inc.$15K
  • Merz North America, Inc.$7K

What the payments were for

  • Food & beverage$944100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$944 in reported general payments places this provider in the 65th percentile of 104 physical medicine & rehabilitation providers in Alabama.

See all physical medicine & rehabilitation providers in Alabama

Medicare billing

Part B allowed, 2024
$30,198
Medicare patients
36
Services billed
3,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Baclofen35$624
Gabapentin54$574

Paid to pharmacies, not to this prescriber.

Other physical medicine & rehabilitation in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →